Edition:
United States

Miragen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

7.98USD
15 Dec 2017
Change (% chg)

$0.04 (+0.50%)
Prev Close
$7.94
Open
$8.00
Day's High
$8.15
Day's Low
$7.88
Volume
135,071
Avg. Vol
28,875
52-wk High
$17.83
52-wk Low
$4.65

Summary

Name Age Since Current Position

William Marshall

53 2017 President, Chief Executive Officer, Director

Jason Leverone

43 2017 Chief Financial Officer, Treasurer, Secretary

Paul Rubin

63 2017 Executive Vice President - Research and Development

Adam Levy

38 2017 Chief Business Officer

Bruce Booth

42 2017 Director

Thomas Hughes

2017 Director

Kevin Koch

2017 Director

Joseph Turner

2017 Director

Christopher Bowden

56 2017 Independent Director

Jeffrey Hatfield

2017 Independent Director

Biographies

Name Description

William Marshall

Dr. William S. Marshall, Ph.D., serves as President, Chief Executive Officer, Director of the Company. Dr. Marshall has served as Private Miragen’s president and chief executive officer and as director since Private Miragen was founded in September 2007. Prior to founding Private Miragen, Dr. Marshall was vice president of technology and business development for bioscience at Thermo Fisher Scientific Inc., a serving science company, from April 2005 to July 2007. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., a biotechnology company, which was acquired by Fisher Scientific International Inc. in April 2004, and he served as the executive vice president for research and operations and general manager of Dharmacon from August 2002 to April 2005. Prior to joining Dharmacon, Dr. Marshall served in multiple positions at Amgen, Inc., a biotechnology company, most recently as associate director of research, site head for research and head of the nucleic acid and peptide technology department. Dr. Marshall earned a B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry at the University of Colorado at Boulder.

Jason Leverone

Mr. Jason A. Leverone, CPA serves as Chief Financial Officer, Treasurer, Secretary of the Company. Mr. Leverone joined Private Miragen in November 2008 as its senior director of finance and operations and was appointed vice president, finance in March 2010. Mr. Leverone was appointed as Private Miragen’s chief financial officer in February 2012. Prior to joining Private Miragen, Mr. Leverone was senior director of finance and controller for Replidyne, Inc., a publicly-traded biotechnology company, from November 2005 to November 2008. Prior to joining Replidyne, Mr. Leverone was the corporate controller for CreekPath System, Inc., an international software development company, from September 2002 to October 2005. He commenced his professional career with the accounting firm of Ernst and Young LLP, where he last served a senior accountant, and then Arthur Andersen LLP, where he last served as an audit manager. Mr. Leverone is a Certified Public Accountant and earned a B.S. in Business Administration from Bryant University.

Paul Rubin

Dr. Paul D. Rubin, M.D., serves as Executive Vice President - Research and Development of the Company. Dr. Rubin has served as Private Miragen’s executive vice president, research and development since November 2016. Prior to joining Private Miragen, Dr. Rubin served as senior vice president, research and development and chief medical officer of Xoma Corporation, a publicly-traded biotechnology company, from November 2011 to November 2016, having joined Xoma in June 2011 as its vice president, clinical development and chief medical officer. Prior to joining XOMA, Dr. Rubin was the chief medical officer at Funxional Therapeutics Ltd., a pharmaceutical company from February 2011 to June 2011. He served as chief executive officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and president and chief executive officer of Critical Therapeutics, Inc. from 2002 to 2007. From 1996 to 2002, Dr. Rubin served as senior vice president, development, and later as executive vice president, research and development at Sepracor Inc. From 1993 to 1996, Dr. Rubin held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as vice president of worldwide clinical pharmacology and early clinical development. During his tenure with Abbott Laboratories from 1987 to 1993, Dr. Rubin served as vice president, immunology and endocrinology. Dr. Rubin received a B.A. from Occidental College and his M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.

Adam Levy

Mr. Adam S. Levy serves as Chief Business Officer of the Company. Mr. Levy has served as Private Miragen’s chief business officer since May 2016. Prior to joining Private Miragen, Mr. Levy served as a senior vice president of healthcare investment banking at Wedbush Securities Inc. from September 2013 to May 2016. From May 2011 to August 2012, Mr. Levy was employed by Merrill Lynch, Pierce, Fenner & Smith, Incorporated as vice president of healthcare investment banking. Prior to joining Merrill Lynch, Mr. Levy served as vice president of healthcare investment banking at Wedbush from October 2009 through April 2011. Mr. Levy earned a B.S. in Applied Economics from Cornell University.

Bruce Booth

Mr. Bruce L. Booth, Ph.D., serves as Director of the Company. He also serves as a director of Atlas Venture Associates VII, Inc. and Atlas Venture Associates X, Inc.

Thomas Hughes

Kevin Koch

Joseph Turner

Christopher Bowden

Dr. Christopher Bowden, M.D., is Independent Director of the Company. Dr. Bowden brings substantial experience in clinical drug development to the Board. He currently serves as the Chief Medical Officer of Agios Pharmaceuticals, Inc. (“Agios”). Prior to joining Agios, he served as vice president, product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia follow by internal medicine training at Roger Williams Medical Center and Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch and is board certified in internal medicine and medical oncology.

Jeffrey Hatfield

Mr. Jeffrey S. Hatfield is Independent Director of the Company. Mr. Hatfield brings relevant industry experience and a breadth of expertise to the Board. From March 2004 through October 2016, Mr. Hatfield served as President and Chief Executive Officer of Vitae Pharmaceuticals, Inc. (“Vitae”), until its acquisition by Allergan in 2016. Prior to working at Vitae, Mr. Hatfield was with Bristol-Myers Squibb Company (“Bristol-Myers”) serving in numerous executive capacities, including as Senior Vice President of Bristol-Myers’s Immunology and Virology divisions. Mr. Hatfield currently serves as a director on the boards of aTyr Pharma, Inc., a publicly traded biotechnology company, and InVivo Therapeutics Corp., a publicly traded medical therapeutic company, and has previously served as a director of Ambit Biosciences Corporation before it was acquired by Daiichi Sankyo Company, Ltd. He is an adjunct professor and is a dean’s advisory board member for Purdue University’s College of Pharmacy. He earned a bachelor’s degree in pharmacy from Purdue University’s School of Pharmacy and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania.